Back to top

Image: Bigstock

Earnings Estimates Moving Higher for Cross Country (CCRN): Time to Buy?

Read MoreHide Full Article

Cross Country Healthcare (CCRN - Free Report) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company.

The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this provider of health care staffing and workforce management services, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. This insight is at the core of our stock rating tool -- the Zacks Rank.

The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.

For Cross Country, strong agreement among the covering analysts in revising earnings estimates upward has resulted in meaningful improvement in consensus estimates for the next quarter and full year.

The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:

12 Month EPS

Current-Quarter Estimate Revisions

For the current quarter, the company is expected to earn $1.26 per share, which is a change of +117.24% from the year-ago reported number.

Over the last 30 days, two estimates have moved higher for Cross Country compared to no negative revisions. As a result, the Zacks Consensus Estimate has increased 128.3%.

Current-Year Estimate Revisions

For the full year, the earnings estimate of $2.78 per share represents a change of -9.15% from the year-ago number.

There has been an encouraging trend in estimate revisions for the current year as well. Over the past month, two estimates have moved up for Cross Country versus no negative revisions. This has pushed the consensus estimate 60.1% higher.

Favorable Zacks Rank

Thanks to promising estimate revisions, Cross Country currently carries a Zacks Rank #1 (Strong Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.

Bottom Line

While strong estimate revisions for Cross Country have attracted decent investments and pushed the stock 5.7% higher over the past four weeks, further upside may still be left in the stock. So, you may consider adding it to your portfolio right away.


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Cross Country Healthcare, Inc. (CCRN) - free report >>

Published in